BioPharma Dive - Latest News

Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy

Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, Novo started up an online pharmacy and the FDA cleared testing of a base editing therapy for Duchenne.

Mar 6, 2025 - 16:27
 0
Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy

Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, Novo started up an online pharmacy and the FDA cleared testing of a base editing therapy for Duchenne.

Read More

Tags:

Previous Article

Zymeworks pauses plans to launch one ADC into clinic in favor of another asset

Next Article

Human medicines European public assessment report (EPAR): Hexyon, diphtheria, te...

Related Posts

Vertex ends gene editing research pact with Verve

Vertex ends gene editing research pact with Verve

Feb 27, 2025  0

‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

‘It’s not for the faint of heart.’ How 3 CEOs took thei...

Feb 14, 2025  0

Jazz expands in oncology with $935M deal for Chimerix

Jazz expands in oncology with $935M deal for Chimerix

Mar 5, 2025  0